Asimov Stock
HealthTechLooking to sell Asimov stock or options?
Asimov, a developer of mammalian cell engineering software, aims to expedite the creation and production of gene therapies and biologics. The firm's platform unifies synthetic biology, machine learning-based design, and biophysical simulations to engineer genetic circuits in biotechnology. This allows healthcare institutions to streamline the design and printing of genetic logic gates, leading to the development of sophisticated therapeutics and manufacturing applications.
Fidelity Investments, Casdin Capital, Wing Venture Capital, Pillar VC, Frog Design, Horizons Ventures, AME Cloud Ventures, CLF Partners, MIT Startup Exchange, Liquid 2 Ventures, Koch Disruptive Technologies, CPP Investments, KdT Ventures, DCVC.